The International Myeloma Foundation Holds Brian D. Novis Research Grant 2025 Awards Reception and Dinner in Los Angeles Read more about The International Myeloma Foundation Holds Brian D. Novis Research Grant 2025 Awards Reception and Dinner in Los AngelesAdd new comment
From Targeted Oncology: 'From Diagnosis to Determination: A Cyclist's Journey with Myeloma' Read more about From Targeted Oncology: 'From Diagnosis to Determination: A Cyclist's Journey with Myeloma'Add new comment
August 2025 – Myeloma News from the Journals Read more about August 2025 – Myeloma News from the JournalsAdd new comment
From RÚV English Radio: 'The International Myeloma Foundation Iceland Cycling Expedition' Read more about From RÚV English Radio: 'The International Myeloma Foundation Iceland Cycling Expedition'Add new comment
From the American Journal of Managed Care: 'How M-Power Is Building Trust to Raise Awareness of Multiple Myeloma in the Black Community' Read more about From the American Journal of Managed Care: 'How M-Power Is Building Trust to Raise Awareness of Multiple Myeloma in the Black Community'Add new comment
From CURE: 'Patients and Caregivers Aim to Raise Funds for Myeloma Research' Read more about From CURE: 'Patients and Caregivers Aim to Raise Funds for Myeloma Research'Add new comment
The International Myeloma Foundation Mourns the Loss of Accomplished Attorney and Longtime Board Member Benson Klein Read more about The International Myeloma Foundation Mourns the Loss of Accomplished Attorney and Longtime Board Member Benson Klein Add new comment
EU Approves SARCLISA® (isatuximab-irfc) for the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Read more about EU Approves SARCLISA® (isatuximab-irfc) for the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Add new comment
Blenrep (belantamab mafodotin) Approved in the EU for Relapsed/Refractory Multiple Myeloma Read more about Blenrep (belantamab mafodotin) Approved in the EU for Relapsed/Refractory Multiple Myeloma Add new comment
U.S. FDA Extends Review Period for Blenrep (belantamab mafodotin) for Relapsed or Refractory Myeloma Read more about U.S. FDA Extends Review Period for Blenrep (belantamab mafodotin) for Relapsed or Refractory Myeloma Add new comment
